Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liverani C
Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,
Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,
Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Boons G, Vandamme T, Ibrahim J, Schepers A, Roeyen G,
Keywords: Pancreatic Neuroendocrine Tumor, DNA Methylation, Prognostic Biomarker,
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,
Keywords: prognostic, biomarker, PRRT, LuTate,
#1434 CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Luo G
#1311 Blood-Based Prognostic Biomarkers in Neuroendocrine Tumour: A Retrospective Study
Introduction: Markers of systemic inflammation –such as the neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR) and lymphocyte:monocyte ratio (LMR) - have been shown to correlate with poor prognosis in multiple solid organ tumours. Analysis of CLARINET showed no significant association between NLR and progression-free survival.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: